Sucampo/Takeda’s Amitiza Gains IBS-C Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
Approval expands the target population for lubiprostone by about 20 million patients, Sucampo commercial head tells “The Pink Sheet” DAILY.